Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: Impact on patient outcomes and component utilization during a 3-year period

Transfusion

Volumn 51, Issue 3, 2011, Pages 622-629

  Cazenave, Jean Pierre ^a   Isola, Hervé ^a   Waller, Chantal ^a   Mendel, Isabelle ^a   Kientz, Daniel ^a   Laforêt, Michel ^a   Raidot, Jean Pierre ^a   Kandel, Gérard ^a   Wiesel, Marie Louise ^a   Corash, Laurence ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISOTONIC SOLUTION; PLATELET ADDITIVE SOLUTION; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; APHERESIS; ARTICLE; BLOOD COMPONENT; BLOOD COMPONENT THERAPY; BLOOD DONOR; BLOOD TRANSFUSION REACTION; CHILD; ERYTHROCYTE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGEN INACTIVATION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTE; THROMBOCYTE COMPONENT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; BLOOD-BORNE PATHOGENS; CHILD; CHILD, PRESCHOOL; DISINFECTION; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PLATELET TRANSFUSION;

EID: 79952471219     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02873.x     Document Type: Article

References (13)

1. Alvarez-Larrán A, Del Río J, Ramírez C, Albo C, Peña F, Campos A, Cid J, Muncunill J, Sastre JL, Sanz C, Pereira A. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004;86:246-51. (Pubitemid 38902095)
2. de la Rubia J, Arriaga F, Linares D, Larrea L, Carpio N, Marty ML, Sanz MA. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001;114:721-3. (Pubitemid 32953658)
3. Andreu G, Morel P, Forestier F, Rebibo D, Janvier G, Herve P. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994-1998. Transfusion 2002;42:1356-64.
4. Cazenave JP, Aleil B, Wiesel ML, Laforet M, Isola H. In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen. Vox Sang 2004;86:201-2.
5. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin LS, Conlan MG, Flament J. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45:1443-52. (Pubitemid 44194647)
6. TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-9.
7. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G. The threshold for prophylactic platelet transfusions in adults with acute myelogenous leukemia. N Engl J Med 1997;337:1870-5.
8. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33. (Pubitemid 36302092)
9. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004;104:1534-41. (Pubitemid 39166535)
10. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008;94:315-23. (Pubitemid 351535733)
11. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L. A prospective observational cohort safety study of 5,106 platelet transfusions using components prepared with photochemical pathogen inactivation treatment. Transfusion 2008;48:1061-71. (Pubitemid 351793479)
12. Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion. Transfusion 2009;49:1083-91.
13. Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, Van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009;49:1412-22.